Syprine, Cuprior(trientine)
Cufence, Cuprior, Syprine (trientine) is a small molecule pharmaceutical. Trientine was first approved as Syprine on 1985-11-08. It is used to treat hepatolenticular degeneration and nervous system heavy metal poisoning in the USA. It has been approved in Europe to treat hepatolenticular degeneration.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Syprine (generic drugs available since 2018-02-07, discontinued: Clovique)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trientine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYPRINE | Bausch Health Companies | N-019194 RX | 1985-11-08 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| syprine | New Drug Application | 2020-09-01 |
| trientine hydrochloride | ANDA | 2023-04-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatolenticular degeneration | Orphanet_905 | D006527 | E83.01 |
| nervous system heavy metal poisoning | EFO_1001815 | D020260 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatolenticular degeneration | D006527 | Orphanet_905 | E83.01 | 1 | — | 1 | 1 | 2 | 5 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | 1 | 1 | — | — | — | 1 | ||
| Peritoneal neoplasms | D010534 | 1 | 1 | — | — | — | 1 | ||
| Macular edema | D008269 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIENTINE |
| INN | trientine |
| Description | 2,2,2-tetramine is a polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens. It has a role as a copper chelator. It is a tetramine and a polyazaalkane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NCCNCCNCCN |
Identifiers
| PDB | — |
| CAS-ID | 112-24-3 |
| RxCUI | 10798 |
| ChEMBL ID | CHEMBL609 |
| ChEBI ID | 39501 |
| PubChem CID | 5565 |
| DrugBank | DB06824 |
| UNII ID | SJ76Y07H5F (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Clovique - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 843 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
62,034 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more